Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19

Version 1 : Received: 15 June 2023 / Approved: 16 June 2023 / Online: 16 June 2023 (14:20:39 CEST)

A peer-reviewed article of this Preprint also exists.

Ghimire, B.; Pour, S.K.; Middleton, E.; Campbell, R.A.; Nies, M.A.; Aghazadeh-Habashi, A. Renin–Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19. Biomedicines 2023, 11, 2118. Ghimire, B.; Pour, S.K.; Middleton, E.; Campbell, R.A.; Nies, M.A.; Aghazadeh-Habashi, A. Renin–Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19. Biomedicines 2023, 11, 2118.

Abstract

Through the ACE2, a main enzyme of the renin-angiotensin system (RAS), the SARS-CoV2 gains access into the cell, resulting in different complications which may extend beyond the RAS and impact the Arachidonic Acid (ArA) pathway. The contribution of the RAS through ArA pathways metabolites in the pathogenesis of COVID-19 is unknown. We investigated whether RAS components and ArA metabolites can be considered biomarkers of COVID-19. We measured the plasma levels of RAS and ArA metabolites using an LC-MS/MS. Results indicate that Ang1-7 levels were significantly lower, whereas Ang II levels were higher in the COVID-19 patients than healthy control individuals. The ratio of Ang1-7/Ang II as an indicator of the RAS classical and protective arms balance was dramatically lower in COVID-19 patients. There was no significant increase in inflammatory 19-HETE and 20-HETE lev-els. The concentration of EETs was significantly increased in COVID-19 patients, whereas the DHETs concentration was repressed. Their plasma levels were correlated with Ang II concentration in COVID-19 patients. In conclusion, evaluating the RAS and ArA pathway biomarkers could provide helpful information for the early detection of high-risk groups, avoid delayed medical attention, facilitate resource allocation and improve patient clinical outcomes to prevent long COVID incidence.

Keywords

Renin-Angiotensin System; Arachidonic Acid; COVID-19; Biomarkers

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.